Gilead Sciences has announced the appointment of Peter Wickersham as vice-president and general manager for the UK and Ireland. In his new role, Wickersham will be responsible for leading Gilead’s commercial organisation in the affiliate with a focus on driving growth and advancing patient care across all of Gilead’s portfolio of innovative products.
With more than 25 years of experience in the pharmaceutical industry, Wickersham brings a wealth of commercial expertise and strategic acumen to his new role. More recently, he led Gilead’s liver disease and COVID-19 business unit in the US, and prior to that, he was vice-president of US managed markets. Before joining Gilead, he held senior positions at Express Scripts, Prime Therapeutics, and Merck & Co (known as MSD outside the US).
“I am thrilled to join Gilead’s UK and Ireland organisation at such a pivotal time. We stand on the brink of eliminating hepatitis C, we continue to pioneer advancements in HIV care and prevention, and we are reshaping the landscape of cancer treatment. The dedication and determination of our team are unmatched, and I am eager to lead them into the next phase of our journey,” said Wickersham, as he assumes the leadership of the UK and Ireland organisation.
Commenting on the appointment, Josephine Comiskey, senior vice-president, Gilead Sciences, Australia-Canada-Europe said: “Under Pete’s leadership, we are looking forward to strengthening our partnerships across the UK and Ireland, addressing the unique challenges faced by the country’s healthcare landscape. As we work towards our ambitious goals of eliminating, preventing and managing some of the world’s most serious diseases, Pete’s expertise will be instrumental in navigating the complexities of the UK’s and Ireland’s healthcare system and addressing the specific needs of patients and healthcare providers alike.”
Wickersham is relocating from California to embark on this new chapter in the UK. He succeeds Véronique Walsh, who now assumes the role of president of Gilead Sciences France.